AFP and hepatocellular carcinoma: At the turn of the 20th and 21st centuries, AFP and its peptide fragments were tested as a therapeutic agent in the treatment of hepatocellular carcinoma (as an anticancer drug carrier and element of immunotherapy vaccines) and investigated as part of research on multiple drug resistance to chemotherapeutics in HCC [5,6,7].